Safety and efficacy of neoadjuvant chemohormonal therapy (low-dose estramustine plus LHRH agonist/antagonist) followed by extended radical prostatectomy for patients with high-risk localized prostate cancer

Safety and efficacy of neoadjuvant chemohormonal therapy (low-dose estramustine plus LHRH agonist/antagonist) followed by extended radical prostatectomy for patients with high-risk localized prostate cancer - Neoadjuvant chemohormonal therapy followed by extended radical prostatectomy for high-risk localized PCa patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035039

Enrollment

Registered

2018-12-15

Start date

2011-11-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

6 months of estramustine phosphate 280 mg bid, along with a luteinizing hormone-releasing hormone agonist/antagonist prior to extended radical prostatectomy.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: high-risk prostate cancer defined by D'amico's criteria

Exclusion criteria

Exclusion criteria: low or intermediate-risk prostate cancer defined by D'amico's criteria

Design outcomes

Primary

Measure	Time frame
biochemical recurrence	—

Secondary

Measure	Time frame
overall survival	—

Countries

Japan

Contacts

Public ContactHIDEKI ENOKIDA

Kagoshima University Hospital Department of Urology

henokida@m2.kufm.kagoshima-u.ac.jp81-99-275-5395

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026